 Monopar Therapeutics NASDAQ: MNPR shares are trading higher Thursday after Roth Capital initiated coverage on the stock with a Buy rating and a price target of 49 per share. Monopar Therapeutics is a U.S. clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. 